Orion Oyj
General ticker "ORINF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $11.5B (TTM average)
Orion Oyj follows the US Stock Market performance with the rate: 30.6%.
Estimated limits based on current volatility of 0.0%: low 92.05$, high 92.05$
Factors to consider:
- Company pays dividends (annually): last record date 2026-03-26, amount 1.04$ (Y1.13%)
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [37.71$, 53.68$]
- 2025-12-31 to 2026-12-31 estimated range: [42.16$, 59.14$]
Financial Metrics affecting the ORINF estimates:
- Positive: with PPE of 19.3 at the end of fiscal year the price was neutral
- Positive: 22.58 < Operating profit margin, % of 27.01
- Positive: 2.37 < Operating cash flow per share per price, % of 4.45
- Positive: 58.56 < Shareholder equity ratio, % of 61.69 <= 69.38
- Positive: Industry inventory ratio change (median), % of -1.32 <= -0.92
- Positive: 7.15 < Industry operating cash flow per share per price (median), % of 7.82
- Positive: 5.07 < Industry earnings per price (median), % of 6.17
- Positive: -2.60 < Investing cash flow per share per price, % of -1.29
- Positive: Interest expense per share per price, % of 0.12 <= 0.33
Short-term ORINF quotes
Long-term ORINF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €1,189.60MM | €1,542.40MM | €1,889.50MM |
| Operating Expenses | €914.70MM | €1,125.80MM | €1,260.50MM |
| Operating Income | €274.90MM | €416.60MM | €629.00MM |
| Non-Operating Income | €-3.00MM | €-3.50MM | €-1.20MM |
| Interest Expense | €5.20MM | €7.60MM | €8.20MM |
| R&D Expense | €126.90MM | €179.60MM | €210.40MM |
| Income(Loss) | €271.90MM | €413.10MM | €627.80MM |
| Taxes | €55.10MM | €0.00MM | €127.50MM |
| Net Income(Loss)* | €216.80MM | €329.90MM | €500.30MM |
| Stockholders Equity | €890.10MM | €1,005.00MM | €1,284.50MM |
| Inventory | €362.20MM | €418.60MM | €456.30MM |
| Assets | €1,438.60MM | €1,629.10MM | €2,009.90MM |
| Operating Cash Flow | €119.00MM | €293.40MM | €316.80MM |
| Capital expenditure | €116.80MM | €86.90MM | €97.60MM |
| Investing Cash Flow | €-108.40MM | €-85.20MM | €-98.60MM |
| Financing Cash Flow | €-243.20MM | €-108.80MM | €-263.60MM |
| Earnings Per Share** | €1.54 | €2.34 | €3.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.